About: Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease
Creator	Westblade, Lars Choi, Justin Goyal, Parag Gulick, Roy Kondoid, Maiko Magleby, Reed Maldarelli, Grace Pham, Khanh Rennert, Hanna Safford, Monika Satlin Id, Michael Schenck, Edward
Source	Medline; PMC
abstract	BACKGROUND: Severe acute respiratory coronavirus 2 (SARS-CoV-2) has caused a devastating worldwide pandemic. Hydroxychloroquine (HCQ) has in vitro activity against SARS-CoV-2, but clinical data supporting HCQ for coronavirus disease 2019 (COVID-19) are limited. METHODS: This was a retrospective cohort study of hospitalized patients with COVID-19 who received ≥1 dose of HCQ at two New York City hospitals. We measured incident Grade 3 or 4 blood count and liver test abnormalities, ventricular arrhythmias, and vomiting and diarrhea within 10 days after HCQ initiation, and the proportion of patients who completed HCQ therapy. We also describe changes in Sequential Organ Failure Assessment hypoxia scores between baseline and day 10 after HCQ initiation and in-hospital mortality. RESULTS: None of the 153 hospitalized patients with COVID-19 who received HCQ developed a sustained ventricular tachyarrhythmia. Incident blood count and liver test abnormalities occurred in <15% of patients and incident vomiting or diarrhea was rare. Eighty-nine percent of patients completed their HCQ course and three patients discontinued therapy because of QT prolongation. Fifty-two percent of patients had improved hypoxia scores 10 days after starting HCQ. Thirty-one percent of patients who were receiving mechanical ventilation at the time of HCQ initiation died during their hospitalization, compared to 18% of patients who were receiving supplemental oxygen but not requiring mechanical ventilation, and 8% of patients who were not requiring supplemental oxygen. Co-administration of azithromycin was not associated with improved outcomes. CONCLUSIONS: HCQ appears to be reasonably safe and tolerable in most hospitalized patients with COVID-19. However, nearly one-half of patients did not improve with this treatment, highlighting the need to evaluate HCQ and alternate therapies in randomized trials.
has issue date	2020-07-23(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0236778
bibo:pmid	32701969
has license	cc-by
sha1sum (hex)	1a5f4148c39017226e4bad09933e6e5d2d276971
schema:url	https://doi.org/10.1371/journal.pone.0236778
resource representing a document's title	Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease
has PubMed Central identifier	PMC7377460
has PubMed identifier	32701969
schema:publication	PLoS One
resource representing a document's body	covid:1a5f4148c39017226e4bad09933e6e5d2d276971#body_text
is schema:about of	named entity 'pandemic' named entity 'Hydroxychloroquine' named entity 'hydroxychloroquine' named entity 'SARS-CoV-2' named entity 'hydroxychloroquine' named entity 'intravenous infusion' named entity '95% CI' named entity 'HCQ' named entity 'fever' named entity 'HCQ' named entity 'univariate analysis' named entity 'Institutional Review Board' named entity 'HCQ' named entity 'afebrile' named entity 'QTc interval' named entity 'control group' named entity 'HCQ' named entity 'leukocytosis' named entity 'partial pressure' named entity 'adverse effects' named entity 'HCQ' named entity 'SARS-CoV-2' named entity 'HCQ' named entity 'vomiting' named entity 'gastrointestinal' named entity 'HCQ' named entity 'New York City Department of Health' named entity 'COVID-19' named entity 'HCQ' named entity 'anemia' named entity 'azithromycin' named entity 'HCQ' named entity 'HCQ' named entity 'HCQ' named entity 'HCQ' named entity 'diarrhea' named entity 'Hydroxychloroquine' named entity 'REDCap' named entity 'HCQ' named entity 'hypoxia' named entity 'follow-up' named entity 'WCMC' named entity 'HCQ' named entity 'remdesivir' named entity 'tolerability' named entity 'informed consent' named entity 'EKG' named entity 'mechanical ventilation' named entity 'HCQ' named entity 'HCQ' named entity 'randomized trials' named entity 'randomized trial' named entity 'tachypnea' named entity 'heart rate' named entity 'HCQ' named entity 'EKG' named entity 'WCMC' named entity 'arterial blood gas' named entity 'follow-up' named entity 'EKG' named entity 'COVID' named entity 'COVID' named entity 'toxicity' named entity 'hypotensive' named entity 'HCQ' named entity 'case series' named entity 'white blood cell' named entity 'HCQ' named entity 'HCQ' named entity 'virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software